RE: RE: About 5 months to waithttps://www.thallion.com/docs/en/news/74.TLN_Q32008.pdf
Outlook
Thallion is focused on advancing the development of its clinical assets to the next significant
milestone events, specifically as it relates to its oncology candidates. These milestones
include:
• Continuing enrollment in both our Phase II trials for TLN-4601 and TLN-232, as
monotherapies for glioblastoma multiforme and metastatic melanoma patients,
respectively.
• Reporting interim analysis of Phase II TLN-4601 trial in the first quarter of calendar
2009.
• Reporting PET-PBR imaging data from its Phase II TLN-4601 trial in the fourth quarter
of calendar 2008.
• Reporting dose escalation data from its Phase II TLN-232 trial in the first quarter of
calendar 2009.
• Continuing its licensing discussions with potential partners, with the intent to complete a
strategic transaction prior to initiating the next stage of clinical development for
Shigamabs®
.
Not sure about the PET-PBR scan and it's implication.
Above are the next milestones to be achieve.
Interim data are usually not good enough to sustain SP increase for long.
Final data are due toward the end of the year.
Cash is getting low
I am crossing fingers for a second bidder and possibly a partnership deal.
Unnamed bidder has increase the likelyhood of the above outcomes.
If results are awesome, they will probably try to refinance and move the drug themselves to end of PIIb trial and get an even better deal.
I am a bit frustrated as to not to know how much they got from the bid. This info. would have moved SP to a proper market value.
In any case, I expect some sort of resolution within next 5 months.
preliminary data + new better offer and sale of the company. TLN will probably be taken over. Initial shareholders won't get the full value of their investment back that's for sure.
But for new shareholders buying now ie myself. Well, the return could be handsome!
I expect something in the 2$ range - 70 to 75 millions offer. Peanuts for a multinational. Pocket change for a giant pharma without pipeline drugs.
Likelyhood of a positive SP increase is very high, imo.